Suppr超能文献

后房型有晶状体眼人工晶状体植入术矫正中高度近视的 8 年随访。

Eight-year follow-up of posterior chamber phakic intraocular lens implantation for moderate to high myopia.

机构信息

Department of Ophthalmology, University of Kitasato School of Medicine, Kanagawa, Japan.

Department of Ophthalmology, University of Kitasato School of Medicine, Kanagawa, Japan.

出版信息

Am J Ophthalmol. 2014 Mar;157(3):532-9.e1. doi: 10.1016/j.ajo.2013.11.006. Epub 2013 Nov 13.

Abstract

PURPOSE

To assess the long-term clinical outcomes of Implantable Collamer Lens (Visian ICL; STAAR Surgical) implantation for moderate to high myopia.

DESIGN

Retrospective observational case series.

METHODS

This study evaluated 41 eyes of 41 patients with myopic refractive errors of -4.00 to -15.25 diopters (D) who underwent ICL implantation and routine postoperative examinations. Before surgery, and 1 and 6 months and 1, 4 and 8 years after surgery, we assessed the safety, efficacy, predictability, stability, and adverse events of the surgery.

RESULTS

The safety and efficacy indices were 1.13 ± 0.27 and 0.83 ± 0.36. At 8 years, 68.3% and 85.4% of the eyes were within 0.5 and 1.0 D, respectively, of the targeted correction. Manifest refraction changes of -0.32 ± 0.73 D occurred between 1 month and 8 years. The mean endothelial cell loss from preoperative levels was 6.2% at 8 years. Two eyes (4.9%) developed clinically significant symptomatic cataract during the follow-up period. Simultaneous lens extraction and phacoemulsification with IOL implantation was successfully performed in these 2 eyes.

CONCLUSIONS

According to our experience, ICL implantation was overall good in measures of safety, efficacy, predictability, and stability for the correction of moderate to high myopia during the 8-year observation period, suggesting its long-term viability as a surgical option for the treatment of such eyes.

摘要

目的

评估可植入式 Collamer 透镜(Visian ICL;STAAR Surgical)植入治疗中高度近视的长期临床效果。

设计

回顾性观察性病例系列研究。

方法

本研究评估了 41 例近视屈光不正为-4.00 至-15.25 屈光度(D)的患者的 41 只眼,这些患者接受了 ICL 植入和常规术后检查。在手术前以及手术后 1 个月、6 个月、1 年、4 年和 8 年,我们评估了手术的安全性、有效性、可预测性、稳定性和不良事件。

结果

安全性和有效性指数分别为 1.13±0.27 和 0.83±0.36。在 8 年时,68.3%和 85.4%的眼分别在 0.5 和 1.0 D 的目标矫正范围内。1 个月至 8 年间,明视屈光度变化为-0.32±0.73 D。8 年后,平均内皮细胞丢失率从术前水平的 6.2%。在随访期间,有 2 只眼(4.9%)发生了临床上明显的症状性白内障。在这 2 只眼中,同时进行了晶状体提取和超声乳化联合 IOL 植入术。

结论

根据我们的经验,在 8 年的观察期内,ICL 植入术在安全性、有效性、可预测性和稳定性方面总体上对中高度近视的矫正效果良好,表明其作为治疗此类眼睛的手术选择具有长期可行性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验